September 22, 2020, 14:10

Trump: FDA Grants Emergency Authorization of Remdesivir to Treat COVID-19

Trump: FDA Grants Emergency Authorization of Remdesivir to Treat COVID-19

US President Donald Trump revealed Friday that Gilead Sciences’ antiviral drug remdesivir has been cleared by the Food and Drug Administration (FDA) for the treatment of COVID-19.

According to Reuters, Gilead CEO Daniel O’Day called the FDA’s emergency authorization an “important first step” and pledged to donate “1 million vials of remdesivir.” US Vice President Mike Pence also said that 1 million vials of remdesivir will be distributed to hospitals starting Monday.

“​I’m pleased to announce that Gilead now has an [emergency authorization] from the FDA for remdesivir. And you know what, that is because that’s been the then the hot thing, also in the papers and in the media for the last little while — an important treatment for hospitalized coronavirus patients,” Trump said Friday in reference to the drug’s authorization.

The FDA authorization comes just two days after Gilead Sciences revealed it was aware of “positive data” from a clinical trial by the US National Institute of Allergy and Infectious Diseases of the antiviral drug as a COVID-19 treatment.

The institute is led by Anthony Fauci, one of the leading doctors assigned to the White House Coronavirus Task Force. During a Wednesday meeting in the Oval Office, Fauci indicated that the drug trial showed that remdesivir has had a significant effect on reducing coronavirus symptoms. 

According to the FDA’s fact sheet, approval of remdesivir simply means that the drug “may be effective in treatment of patients.” The FDA also notes that “remdesivir has not undergone the same type of review as an FDA-approved or cleared product” since the drug was issued an “Emergency Use Authorization” (EUA).

Also on Wednesday, former FDA Commissioner Scott Gottlieb said that that remdesivir is probably not a “home run” treatment for the novel coronavirus, but can help alleviate symptoms.

“It’s not going to be a cure, but it is going to be a drug potentially that if you use it particularly early in the course of a disease – you hang it in the emergency room when someone comes in with COVID, especially someone with risk factors that predict they’ll have a worse outcome from the disease –  it could reduce their chances of having a really bad outcome,” he said in a statement to CNBC.

However, it appears as though the drug may have side effects in some patients.

However, the FDA on Friday revealed that its “reasonable” to believe that the benefits of remdesivir “outweigh risks” for the “treatment of patients hospitalized with severe COVID-19,” Reuters reported.

Remdesvir was initially developed by Gilead as a potential treatment for Ebola; however, it failed to treat the disease, which causes severe bleeding and organ failure. The drug has been experimentally shown to be effective at inhibiting the growth of coronaviruses that cause illnesses similar to COVID-19, including severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). 

The University of Oxford expects to have the first indication of whether its COVID-19 vaccine – called ChAdOx1 nCoV-19 – works on humans in mid-June. Human trials for the coronavirus vaccine developed by the university began on April 23, after the drug showed promising results by protecting six rhesus macaque monkeys from large amounts of COVID-19 in late March. Around 1,100 people are currently part of the trial.

The World Health Organization revealed last Thursday that there are a total of at least six COVID-19 vaccines that have entered human trials, and 77 others are still in various stages of development.

Sourse: sputniknews.com

Related posts

Leave a Reply

Your email address will not be published. Required fields are marked *

We use cookies in order to give you the best possible experience on our website. By continuing to use this site, you agree to our use of cookies. You can find a detailed description in our Privacy Policy.
Accept
Reject
Privacy Policy